Stryker Corp. (SYK)

Name: Stryker Corp. (SYK): results, filings decoded, planned insider sales, 13F holders, insiders, Congress and short interest
Creator: GreekSoup
License: https://creativecommons.org/licenses/by/4.0/

Compare with another name

Stryker Corp. (SYK) reported revenue of $6.6 billion for Q2 FY2026, the quarter ended 30 June 2026, up 9.4% on the same quarter a year earlier. Net income was $1.3 billion, up 44.3% on the year, and diluted earnings per share $3.30. The figures are the company's own, from the 10-Q it filed with the SEC on 31 July 2026.

Revenue$6.6 billionup 9.4%

Net income$1.3 billionup 44.3%

Diluted EPS$3.30

QuarterQ2 FY2026ended 30 June 2026

Ratios

From the filings

ROE15.5%

ROCE14.2%

Operating margin21.4%

Net margin14.4%

FCF margin18.2%

Interest covern/a

Debt to equity0.62

Cash conversion1.48

Share count, 1 year0.3%

Sales CAGR, 3 years10.8%

Profit CAGR, 3 years11.2%

EPS, TTM$9.65

At the close of 21 September 2026

Price$274.19

Market cap$105.2 billion

Stock P/E28.41

Price to book4.38

EV / EBITDA16.31

Dividend yield1.3%

Market cap / sales4.07

52-week high$388.35

52-week low$270.01

Price, 1 year-27.2%

Price CAGR, 3 years-1.3%

Price CAGR, 5 years0.2%

Every figure is arithmetic on the filed lines (hover a name for the formula); the priced ones use the latest daily close, CBOE delayed quotes, daily history, by CBOE, for splits. Debt to equity here stands on the total debt Stryker Corp. states in its own filing, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.

Price, 17 September 2021 to 21 September 2026

Show

50-day average 200-day average Volume

Daily closes from CBOE delayed quotes, daily history, by CBOE, for splits; the last is 21 September 2026. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Drawn in your browser; the range and overlay you pick are remembered here only.

The public record on SYK

Filings	19 in twelve months: 12 current reports (8-K), about 4 results of operations; 4 regulation fd disclosure; 2 other events; 2 officer or director change; 1 shareholder vote
Planned insider sales	10 Form 144 notices in twelve months, $404.0 million; latest 18 August 2026
Options tape	put/call 0.62 by open interest on 23 September 2026; the straddle prices a 6.6% move to 16 October 2026
Holders	11 of the followed funds hold it; largest Geode Capital Management; 3 Schedule 13D or 13G filings in twelve months
Insider trading	56 sales and 5 purchases on Form 4 in twelve months
Congress	2 House trades disclosed in six months
Short interest	7.6 million shares short, 3.34 days to cover at 31 August 2026
Documents	the 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Quarterly results, the last 12 quarters

	Q3 FY2023	Q4 FY2023	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025	Q1 FY2026	Q2 FY2026
Revenue	4,909	5,815	5,243	5,422	5,494	6,436	5,866	6,022	6,057	7,171	6,020	6,589
Cost of revenue	1,751	2,112	1,910	2,006	1,977	2,262	2,122	2,181	2,205	2,543	2,210	2,091
Gross profit	3,158	3,703	3,333	3,416	3,517	4,174	3,744	3,841	3,852	4,628	3,810	4,498
Gross margin	64%	64%	64%	63%	64%	65%	64%	64%	64%	65%	63%	68%
R&D	353	350	368	363	377	358	405	407	410	401	413	434
SG&A	1,701	1,941	1,840	1,847	1,896	2,102	2,300	2,079	2,045	2,227	2,281	2,229
Operating income	931	1,257	972	1,051	1,085	581	837	1,113	1,135	1,804	936	1,659
Operating margin	19%	22%	19%	19%	20%	9%	14%	18%	19%	25%	16%	25%
Interest expense	n/a	n/a	n/a	96.0	98.0	n/a	137	159	157	n/a	148	141
Pre-tax income	869	1,226	923	998	1,043	528	764	1,016	1,029	1,705	850	1,564
Tax rate	20%	7%	15%	17%	20%	-3%	14%	13%	17%	50%	12%	18%
Net income	692	1,143	788	825	834	546	654	884	859	849	745	1,276
Net margin	14%	20%	15%	15%	15%	8%	11%	15%	14%	12%	12%	19%
Diluted EPS	$1.80	$2.98	$2.05	$2.14	$2.16	$1.41	$1.69	$2.29	$2.22	$2.20	$1.93	$3.30
Operating cash flow	1,050	1,528	204	633	1,474	1,931	250	1,111	1,540	2,143	581	1,261
Capital expenditure	148	145	167	152	170	266	123	183	187	268	166	202
Free cash flow	902	1,383	37.0	481	1,304	1,665	127	928	1,353	1,875	415	1,059
Dividends paid	285	285	304	305	305	305	320	321	322	321	337	337
Shares outstanding	380m	380m	381m	381m	381m	382m	382m	382m	382m	383m	383m	384m
Filing	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q

Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Profit and loss, 12 fiscal years and the trailing twelve months

	FY2014 †	FY2015 †	FY2016 †	FY2017 †	FY2018	FY2019 †	FY2020	FY2021	FY2022 †	FY2023 †	FY2024	FY2025	TTM
Revenue	9,675	9,946	11,325	12,444	13,601	14,884	14,351	17,108	18,449	20,498	22,595	25,116	25,837
Cost of revenue	3,319	3,344	3,821	4,264	4,663	5,188	5,294	6,140	6,871	7,440	8,155	9,051	9,049
Gross profit	6,356	6,602	7,495	8,173	8,938	9,696	9,057	10,968	11,578	13,058	14,440	16,065	16,788
Gross margin	65.7%	66.4%	66.2%	65.7%	65.7%	65.1%	63.1%	64.1%	62.8%	63.7%	63.9%	64.0%	65.0%
Research and development	614	625	715	787	862	971	984	1,235	1,454	1,388	1,466	1,623	1,658
Selling, general and administrative	3,547	3,610	4,137	4,552	5,099	5,356	5,361	6,427	6,386	7,111	7,685	8,651	8,782
Operating income	1,246	1,861	2,175	2,297	2,537	2,713	2,223	2,584	2,841	3,888	3,689	4,889	5,534
Operating margin	12.9%	18.7%	19.2%	18.5%	18.7%	18.2%	15.5%	15.1%	15.4%	19.0%	16.3%	19.5%	21.4%
Interest expense	113	108	228	247	264	287	315	337	337	363	409	607	n/a
Pre-tax income	1,160	1,735	1,921	2,063	2,356	2,562	1,954	2,281	2,683	3,673	3,492	4,514	5,148
Income tax	645	296	274	1,043	-1,197	479	355	287	325	508	499	1,268	1,419
Effective tax rate	55.6%	17.1%	14.3%	50.6%	-50.8%	18.7%	18.2%	12.6%	12.1%	13.8%	14.3%	28.1%	27.6%
Net income	515	1,439	1,647	1,020	3,553	2,083	1,599	1,994	2,358	3,165	2,993	3,246	3,729
Net margin	5.3%	14.5%	14.5%	8.2%	26.1%	14.0%	11.1%	11.7%	12.8%	15.4%	13.2%	12.9%	14.4%
Diluted EPS	$1.34	$3.78	$4.35	$2.68	$9.34	$5.48	$4.20	$5.21	$6.17	$8.25	$7.76	$8.40	$9.65
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Income statement lines from each year's 10-K, the year linked to its filing; TTM is the sum of the last four quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

	FY2014 †	FY2015 †	FY2016 †	FY2017 †	FY2018	FY2019 †	FY2020	FY2021	FY2022 †	FY2023 †	FY2024	FY2025	TTM
Operating cash flow	1,782	981	1,915	1,559	2,610	2,191	3,277	3,263	2,624	3,711	4,242	5,044	5,525
Capital expenditure	233	270	490	598	572	649	487	525	588	575	755	761	823
Free cash flow	1,549	711	1,425	961	2,038	1,542	2,790	2,738	2,036	3,136	3,487	4,283	4,702
Free cash flow margin	16.0%	7.1%	12.6%	7.7%	15.0%	10.4%	19.4%	16.0%	11.0%	15.3%	15.4%	17.1%	18.2%
Depreciation and amortisation	586	590	752	859	966	1,044	1,076	1,272	1,278	1,341	1,426	1,570	1,621
Share-based compensation	77.0	86.0	97.0	113	119	127	142	171	168	205	229	243	251
Buybacks	100	700	13.0	230	300	307	0.0	0.0	n/a	n/a	n/a	n/a	n/a
Dividends paid	462	521	568	636	703	778	863	950	1,051	1,139	1,219	1,284	1,317
Dividend per share	$0.27	$1.42	$1.56	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$3.48
Diluted shares, weighted	383m	381m	378m	380m	380m	380m	380m	382m	382m	384m	386m	386m	386m
Shares outstanding at period end	0m	373m	375m	374m	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	384m
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Buybacks and dividends are the cash paid in the year, from the cash flow statement; the dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet at year end

	FY2014 †	FY2015 †	FY2016 †	FY2017 †	FY2018	FY2019 †	FY2020	FY2021	FY2022 †	FY2023 †	FY2024	FY2025	TTM
Total assets	17,258	16,247	20,435	22,197	27,229	30,167	34,330	34,631	36,884	39,912	42,971	47,844	47,930
Cash and equivalents	1,795	3,379	3,316	2,542	3,616	4,337	2,943	2,944	1,844	2,971	3,652	4,011	3,391
Receivables	1,572	1,662	1,967	2,198	2,332	2,893	2,701	3,022	3,565	3,765	3,987	4,039	3,743
Inventory	1,588	1,639	2,030	2,465	2,955	2,980	3,494	3,314	3,995	4,843	4,774	5,310	5,521
Goodwill	4,186	4,136	6,356	7,168	8,563	9,069	12,778	12,918	14,880	15,243	15,855	19,291	19,584
Total debt, as filed	3,973	3,998	6,914	7,222	9,859	11,090	13,991	12,479	13,048	12,995	13,597	15,859	14,942
Long-term debt	3,246	3,230	6,686	6,590	8,486	10,231	13,230	12,472	11,857	10,901	12,188	14,859	14,192
Operating lease liabilities	n/a	n/a	n/a	n/a	n/a	301	325	310	357	356	379	348	345
Shareholders' equity	8,595	8,511	9,550	9,966	11,730	12,807	13,084	14,877	16,616	18,593	20,634	22,420	23,988
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

At the fiscal year end; the TTM column is the latest quarter end. A line the company does not tag under the usual name is left out.

Compounded growth

	10 years	5 years	3 years	TTM
Sales growth, compounded	9.7%	11.8%	10.8%	8.5%
Profit growth, compounded	8.5%	15.2%	11.2%	27.8%
Return on equity, average	16.0%	14.7%	15.3%	14.5%

Compounded growth is the latest fiscal year over the year that many years earlier, annualised; the TTM column is the last four quarters over the four before. Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Peers: Surgical & Medical Instruments & Apparatus

Company	Market cap	P/E	ROE	Op. margin	Sales growth TTM	Debt to equity	Div. yield
Stryker Corp. SYK	$105.2 billion	28.41	15.5%	21.4%	8.5%	0.62	1.3%
3M Co. MMM	$85.1 billion	29.30	101.5%	18.4%	2.3%	3.69	1.8%
Boston Scientific Corp. BSX	$63.4 billion	17.70	14.7%	19.8%	13.5%	0.44	n/a
Becton Dickinson & Co. BDX	$49.2 billion	54.59	3.9%	9.6%	-2.6%	0.55	2.3%
Dexcom Inc. DXCM	$33.7 billion	35.38	38.1%	22.9%	15.5%	0.03	n/a
Resmed Inc. RMD	$32.3 billion	21.44	23.1%	33.4%	9.9%	0.10	1.1%
West Pharmaceutical Services Inc. WST	$25.5 billion	46.32	18.9%	20.5%	12.4%	0.07	0.2%
Solventum Corp. SOLV	$15.1 billion	10.85	29.9%	25.0%	-0.9%	1.06	n/a
Baxter International Inc. BAX	$11.9 billion	n/a	-17.1%	-2.4%	5.4%	1.54	2.3%
Insulet Corp. PODD	$9.7 billion	26.37	26.4%	16.9%	29.4%	0.65	n/a

The names on this site in the same industry (the SEC's SIC description), by market capitalisation. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close.

Filings

Filing	Period	Filed	Where
10-Q	30 June 2026	31 July 2026	EDGAR
10-Q	31 March 2026	11 May 2026	EDGAR
10-K	31 December 2025	11 February 2026	EDGAR
10-Q	30 September 2025	31 October 2025	EDGAR
10-Q	30 June 2025	1 August 2025	EDGAR
10-Q	31 March 2025	2 May 2025	EDGAR
10-K	31 December 2024	12 February 2025	EDGAR
10-Q	30 September 2024	30 October 2024	EDGAR
10-Q	30 June 2024	31 July 2024	EDGAR
10-Q	31 March 2024	1 May 2024	EDGAR

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install